NCT00051675
Completed
Phase 1
An Open-Label, Multi-Dose, Phase I, Dose-Escalating Study of a Subcutaneously Administered Human-Engineered Monoclonal Antibody, ING-1(heMAb), in Subjects With Advanced Adenocarcinomas
ConditionsAdenocarcinoma
DrugsING-1(heMAb)
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Adenocarcinoma
- Sponsor
- XOMA (US) LLC
- Enrollment
- 30
- Locations
- 1
- Status
- Completed
- Last Updated
- 20 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the safety, immunogenicity, and tolerability of a monoclonal antibody administered subcutaneously in the treatment of advanced cancers of the ovary, breast, lung, prostate, colon or rectum that are either refractory to standard therapies or for which therapies that may potentially be of major benefit do not exist.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
CP-675,206 In Patients With Advanced MelanomaMalignant MelanomaNCT00086489AstraZeneca118
Recruiting
Phase 1
A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid TumorsAdvanced Solid TumorsNCT05688605Shanghai Miracogen Inc.18
Recruiting
Phase 1
A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid TumorsAdvanced or Metastatic Solid TumorsNCT04843709Shanghai Miracogen Inc.181
Completed
Phase 1
Study of the CD40 Agonistic Monoclonal Antibody APX005MCancerNSCLCMelanomaUrothelial CarcinomaMSI-HHead and Neck CancerNCT02482168Apexigen America, Inc.43
Completed
Phase 1
MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.Solid TumorsNCT02503774MedImmune LLC192